
Abbott Labs (ABT) Stock Forecast & Price Target
Abbott Labs (ABT) Analyst Ratings
Bulls say
Abbott Laboratories continues to project a robust organic sales growth rate of 6.0-7.0% through 2025, with a consensus revenue expectation of approximately $44.69 billion, reflecting a year-over-year increase. Noteworthy performance in the company's Electrophysiology and Structural Heart sectors, including significant double-digit growth in key areas such as Diabetes and heart management devices, underlines Abbott's strong position in the medical device market. Furthermore, Abbott's commitment to increasing dividends for over 50 consecutive years, coupled with a strong balance sheet, suggests a stable financial foundation poised for potential mergers and acquisitions, reinforcing a positive outlook for the company's stock.
Bears say
Abbott Laboratories is facing significant challenges that contribute to a negative outlook on its stock, primarily due to a steep decline in Covid-19 testing-related sales, which fell from $265 million in Q3'24 to $69 million in Q3'25. Additionally, persistent macroeconomic pressures such as inflation and foreign exchange fluctuations are adversely affecting performance, alongside funding cuts for HIV testing that impact Abbott’s Rapid Diagnostics segment. The company's results were mixed, with a top-line miss driven by these factors, and concerns remain regarding the sustainability of its growth in core markets due to lagging expectations, particularly in China.
This aggregate rating is based on analysts' research of Abbott Labs and is not a guaranteed prediction by Public.com or investment advice.
Abbott Labs (ABT) Analyst Forecast & Price Prediction
Start investing in Abbott Labs (ABT)
Order type
Buy in
Order amount
Est. shares
0 shares